Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
10 oct. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the...
Brains Bioceutical Opens UK’s Largest EU GMP-Grade Licensed Cannabinoid Research and Commercial Production Facility
29 sept. 2022 01h00 HE
|
Brains Bioceutical Corp
VANCOUVER, British Columbia and SANDWICH, United Kingdom, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp (“Brains” or the “Company”), is pleased to announce the opening of its recently...
Real Brands Signs Definitive Agreement for the Acquisition of Boulder Botanical & Biosciences Laboratories Assets
27 sept. 2022 08h30 HE
|
Real Brands Inc.
$12 million transactionProvides Real Brands with world class R&D and manufacturing capabilities for 300% increase in production capacity and 150+ brandsSpecializes in sports medicine, health and...
Hemp-Derived CBD Oil Market Size is projected to reach USD 6.53 Billion by 2030, growing at a CAGR of 22.30%: Straits Research
23 août 2022 15h55 HE
|
Straits Research
New York, United States, Aug. 23, 2022 (GLOBE NEWSWIRE) -- CBD (cannabinoid) is extracted from cannabis hemp plant leaves, flowers, and stems using two extraction methods, i.e., by removing the CBD...
Scisparc Announces the Full Exercise of Pre-Funded Warrants
19 août 2022 06h45 HE
|
SciSparc Ltd
The pre-funded warrants were issued as part of the $10 million private placement from June 2022 TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
15 août 2022 08h30 HE
|
SciSparc Ltd
The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories ...
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
01 août 2022 09h30 HE
|
SciSparc Ltd
The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
CannaNova LLC Announces its Formation; CannaNova will Commercialize Consumer Cannabinoid Consumables Using DepoFilm™ Oral Film Technology
19 juil. 2022 08h00 HE
|
CannaNova LLC
Greensboro, NC, July 19, 2022 (GLOBE NEWSWIRE) -- CannaNova Cannabinoid Film CannaNova LLC today announced its formation to pursue the consumer cannabinoid space, employing DepoFilm™...
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome
08 juil. 2022 08h30 HE
|
SciSparc Ltd
TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility
07 juil. 2022 08h30 HE
|
SciSparc Ltd
The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...